Treatment of Surgically Resectable Non–Small-Cell Lung Cancer in Elderly Patients
Authors:
- Benjamin E. HaithcockBHBenjamin E. Haithcock
- Thomas E. StinchcombeTSThomas E. Stinchcombe
- Mark A. SocinskiMSMark A. Socinski
- 1 November 2009
- journal article
- review article
- Published by Elsevier in Clinical Lung Cancer
- Vol. 10 (6) , 405-409
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Effect of Age on Survival of Clinical Stage I Non-Small-Cell Lung CancerAnnals of Surgical Oncology, 2009
- Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non–Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study GroupsJournal of Clinical Oncology, 2008
- Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative GroupJournal of Clinical Oncology, 2008
- Pooled Analysis of the Effect of Age on Adjuvant Cisplatin-Based Chemotherapy for Completely Resected Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2008
- A Feasibility Study of Postoperative Adjuvant Therapy of Carboplatin and Weekly Paclitaxel for Completely Resected Non-small Cell Lung CancerJournal of Thoracic Oncology, 2008
- Video-Assisted Thoracic Surgery for Clinical Stage I Lung Cancer in OctogenariansThe Annals of Thoracic Surgery, 2008
- The Feasibility of Adjuvant Carboplatin and Docetaxel in Patients with Curatively Resected Non-small Cell Lung CancerJournal of Thoracic Oncology, 2008
- Lung Cancer in Elderly Patients: An Analysis of the Surveillance, Epidemiology, and End Results DatabaseJournal of Clinical Oncology, 2007
- Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial1European Journal of Cardio-Thoracic Surgery, 2004
- Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment TrialsNew England Journal of Medicine, 1999